Eliem Therapeutics Price to Sales Ratio 2021-2024 | CLYM
Historical PS ratio values for Eliem Therapeutics (CLYM) over the last 10 years. The current P/S ratio for Eliem Therapeutics as of October 04, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Eliem Therapeutics P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-10-03 |
5.10 |
|
inf |
| 2024-03-31 |
2.74 |
0 |
0.00 |
| 2023-12-31 |
2.70 |
0 |
0.00 |
| 2023-09-30 |
2.63 |
0 |
0.00 |
| 2023-06-30 |
2.80 |
0 |
0.00 |
| 2023-03-31 |
2.90 |
0 |
0.00 |
| 2022-12-31 |
3.67 |
0 |
0.00 |
| 2024-06-30 |
7.11 |
0 |
0.00 |
| 2022-09-30 |
3.23 |
0 |
0.00 |
| 2022-06-30 |
3.02 |
0 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
